Ester Martín-Villar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ester Martín-Villar has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Beatriz Fernández-Varas
Instituto de Investigaciones Biomedicas Sols/Morreale CSIC/UAM , Arturo Duperier 4, 28029 Madrid , Spain
1 shared publication - Carlos Rodríguez-Antolín
Instituto de Genética Médica y Molecular, Instituto de Investigación Sanitaria del Hospital Universitario La Paz, Madrid, Madrid, Spain
1 shared publication - Inmaculada Ibanez de Caceres
Cancer Epigenetics Laboratory, INGEMM, La Paz University Hospital, Madrid, Spain
1 shared publication - Javier de Castro
Hospital Universitario La Paz, Madrid, Spain
1 shared publication - Laura Pintado-Berninches
Instituto de Investigaciones Biomédicas CSIC/UAM, Madrid, Spain
1 shared publication - Leandro Sastre
Instituto de Investigaciones Biomédicas Sols-Morreale
1 shared publication
Latest Publications
- Open Access
- 25 April 2019
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 20 (8) , 2036
Role of Dusp6 Phosphatase as a Tumor Suppressor in Non-Small Cell Lung Cancer
DUSP6/MKP3 is a dual-specific phosphatase that regulates extracellular regulated kinase ERK1/2 and ERK5 activity, with an increasingly recognized role as tumor suppressor. In silico studies from Gene expression Omnibus (GEO) and Cancer Genome atlas (TCGA) databases reveal poor prognosis in those Non-small cell lung cancer (NSCLC) patients with low expression levels of DUSP6. In agreement with these data, here we show that DUSP6 plays a major role in the regulation of cell migration, motility and tumor growth. We have found upregulation in the expression of several genes involved in epithelial to mesenchymal transition (EMT) in NSCLC-DUSP6 depleted cells. Data obtained in RNA-seq studies carried out in DUSP6 depleted cells identified EGFR, TGF-β and WNT signaling pathways and several genes such as VAV3, RUNXR2, LEF1, FGFR2 whose expression is upregulated in these cells and therefore affecting cellular functions such as integrin mediated cell adhesion, focal adhesion and motility. Furthermore, EGF signaling pathway is activated via ERK5 and not ERK1/2 and TGF-β via SMAD2/3 in DUSP6 depleted cells. In summary DUSP6 is a tumor suppressor in NSCLC and re-establishment of its expression may be a potential strategy to revert poor outcome in NSCLC patients.
- 25 April 2019
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 20 (8) , 2036
Open AccessRole of Dusp6 Phosphatase as a Tumor Suppressor in Non-Small Cell Lung Cancer
DUSP6/MKP3 is a dual-specific phosphatase that regulates extracellular regulated kinase ERK1/2 and ERK5 activity, with an increasingly recognized role as tumor suppressor. In silico studies from Gene expression Omnibus (GEO) and Cancer Genome atlas (TCGA) databases reveal poor prognosis in those Non-small cell lung cancer (NSCLC) patients with low expression levels of DUSP6. In agreement with these data, here we show that DUSP6 plays a major role in the regulation of cell migration, motility and tumor growth. We have found upregulation in the expression of several genes involved in epithelial to mesenchymal transition (EMT) in NSCLC-DUSP6 depleted cells. Data obtained in RNA-seq studies carried out in DUSP6 depleted cells identified EGFR, TGF-β and WNT signaling pathways and several genes such as VAV3, RUNXR2, LEF1, FGFR2 whose expression is upregulated in these cells and therefore affecting cellular functions such as integrin mediated cell adhesion, focal adhesion and motility. Furthermore, EGF signaling pathway is activated via ERK5 and not ERK1/2 and TGF-β via SMAD2/3 in DUSP6 depleted cells. In summary DUSP6 is a tumor suppressor in NSCLC and re-establishment of its expression may be a potential strategy to revert poor outcome in NSCLC patients.